
A meta-analysis of 8 trials involving 715 youth found that GLP-1 receptor agonists significantly reduced BMI (SMD −0.67), body weight (−0.60), and waist circumference (−0.40). While cardiometabolic markers like HbA1c and lipids showed no change, systolic blood pressure declined slightly. Side effects, mostly mild GI issues, were more frequent but rarely led to withdrawal.
Like
Save
Share